Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

3(50.0%)

6Total

Phase 2(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01807650Phase 3Completed

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)

Role: lead

NCT01657305Phase 3Completed

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)

Role: lead

NCT01294241Phase 2Completed

Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

Role: lead

NCT01657292Phase 3Completed

Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds

Role: lead

NCT00786994Phase 2Completed

The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses

Role: lead

NCT01294254Phase 2Completed

Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

Role: lead

All 6 trials loaded